| http://www.w3.org/ns/prov#value | - The compounds of the present invention have also shown use in reducing C-reactive protein (CRP) associated with inflammation and/or inflammatory conditions including cardiovascular diseases or disorders, such as atrial fibrillation, unstable angina, coronary artery disease, peripheral artery disease, cardiac allograft vasculopathy (CAVD), mastitis, preeclampsia, inflammatory bowel conditions, stro
|
